GLP - 2T

The main reason this compound drew so much attention is simple: researchers tested it at scale and published glycemic endpoints quickly. In SURPASS-2 (2021), Frias and colleagues randomized 1,879 people for 40 weeks and compared three once-weekly dose arms (5 mg, 10 mg, and 15 mg) with semaglutide 1 mg. Reported HbA1c changes were -2.01%, -2.24%, and -2.30% in the three dose arms versus -1.86% in the semaglutide arm — the headline being a dual-incretin glycemic effect studied head-to-head against an active comparator. Body-composition endpoints were also reported across the program.

The next big test was whether the signal held up against insulin-centered care pathways. In SURPASS-3 (Del Prato et al., 2021), researchers ran a 52-week trial at 122 sites in 13 countries with 1,444 randomized participants (1,437 in the modified intention-to-treat analysis). The protocol escalated once-weekly doses from 2.5 mg to target doses of 5 mg, 10 mg, or 15 mg, and compared them with daily insulin degludec titrated to fasting glucose targets. Reported HbA1c reductions were -1.93%, -2.20%, and -2.37% in the tirzepatide groups versus -1.34% with insulin degludec. Weight changed by -7.5 kg to -12.9 kg in tirzepatide groups versus +2.3 kg with insulin degludec. Severe or clinically significant hypoglycemia was also lower in tirzepatide groups (1-2%) than in the insulin group (7%).

In SURPASS-5 (Dahl et al., JAMA 2022), researchers added once-weekly tirzepatide to insulin glargine in 475 participants over 40 weeks. Reported HbA1c changes were -2.11% (5 mg), -2.40% (10 mg), and -2.34% (15 mg) versus -0.86% in placebo; body-composition changes were also reported across the dose arms. A separate 72-week trial (SURMOUNT-1, Jastreboff et al., NEJM 2022) examined body-composition endpoints in 2,539 participants.

Framing note for researchers: these are published human clinical-trial findings for the molecule itself, reported by independent investigators. They are not outcomes claimed for this research-use-only product, nor guidance for any use.

Once glycemic findings were established, published teams tested adjacent disease models. In SYNERGY-NASH (Loomba et al., NEJM 2024), 190 participants with biopsy-confirmed MASH and F2/F3 fibrosis were randomized for 52 weeks; 157 had week-52 biopsy data available for evaluation. MASH resolution without fibrosis worsening was reported in 44%, 56%, and 62% of the 5 mg, 10 mg, and 15 mg groups versus 10% with placebo. Improvement of at least one fibrosis stage without worsening MASH was 55%, 51%, and 51% versus 30% in placebo.

In SURPASS-CVOT (Nicholls et al., NEJM 2025), 13,299 participants were randomized and 13,165 entered modified intention-to-treat analysis (6,586 vs 6,579). The primary cardiovascular composite occurred in 12.2% of the tirzepatide group and 13.1% of the dulaglutide group (hazard ratio 0.92, 95.3% CI 0.83 to 1.01), meeting the trial's noninferiority test.

Catalog format: lyophilized research material as presented on the storefront listing.

In-stock listing sizes: 10mg, 15mg, 30mg.

Laboratory handling note: publications in this field typically report controlled storage, chain-of-custody documentation, and method-specific reconstitution procedures under institutional SOPs. This site does not provide dosing, administration, or protocol instructions.